Pamicell Signs $8.8 Billion Nucleotide Supply Contract with US Thermo Fisher

[Asia Economy Reporter Park Jun-yi] Pharmicell announced on the 28th that it has signed a sales and supply contract for the pharmaceutical intermediate 'nucleoside' worth $7,923,500 (approximately 8.78637 billion KRW) with Thermo Fisher Scientific, a U.S. life sciences company.

The contract amount accounts for 27.05% of the sales as of the end of last year. The contract will expire on August 13 of next year.